Hi, what are you looking for?
By Colin Kellaher
Seelos Therapeutics shares tumbled in premarket trading Wednesday after the clinical-stage biopharmaceutical company said a Phase 2 study of its SLS-002 depression drug candidate missed its key goal due to an shortfall in enrollment.
The New York company said SLS-002 showed clinically meaningful treatment effects across multiple…
Read the full article here
Follow Play Earnings CallPlay Earnings Call Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs...
This article was written by Follow I am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk...
Watch full video on YouTube
